KRAS and neoplasm: Considering the final endpoint, using ASLNAqPCR we detected a KRAS mutation in the 56.8% of adenocarcinomatous and pre-neoplastic lesions (in the 60% of PDAC, 41.7% of IPMNs and in the 66.7% of inoperable neoplasias.